Jaffar M Khan1, Adam B Greenbaum2, Vasilis C Babaliaros3, Toby Rogers4, Marvin H Eng5, Gaetano Paone5, Bradley G Leshnower3, Mark Reisman6, Lowell Satler7, Ron Waksman7, Marcus Y Chen1, Annette M Stine1, Xin Tian1, Danny Dvir6, Robert J Lederman8. 1. Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. 2. Center for Structural Heart Disease, Division of Cardiology, and Division of Cardiac Surgery, Henry Ford Health System, Detroit, Michigan; Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia. 3. Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia. 4. Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland; Medstar Washington Hospital Center, Washington, DC. 5. Center for Structural Heart Disease, Division of Cardiology, and Division of Cardiac Surgery, Henry Ford Health System, Detroit, Michigan. 6. University of Washington, Seattle, Washington. 7. Medstar Washington Hospital Center, Washington, DC. 8. Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: lederman@nih.gov.
Abstract
OBJECTIVES: The BASILICA (Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction during TAVR) investigational device exemption trial was a prospective, multicenter, single-arm safety and feasibility study. BACKGROUND: Coronary artery obstruction is a rare but devastating complication of transcatheter aortic valve replacement (TAVR). Current stent-based preventative strategies are suboptimal. Bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction during TAVR (BASILICA) is a novel transcatheter technique performed immediately before TAVR to prevent coronary artery obstruction. METHODS: Subjects with severe native or bioprosthetic aortic valve disease at high or extreme risk for surgery, and at high risk of coronary artery obstruction, were included. The primary success endpoint was successful BASILICA and TAVR without coronary obstruction or reintervention. The primary safety endpoint was freedom from major adverse cardiovascular events. Data were independently monitored. Endpoints were independently adjudicated. A core laboratory analyzed computed tomography images. RESULTS: Between February 2018 and July 2018, 30 subjects were enrolled. Primary success was met in 28 (93%) subjects. BASILICA traversal and laceration was successful in 35 of 37 (95%) attempted leaflets. There was 100% freedom from coronary obstruction and reintervention. Primary safety was met in 21 (70%), driven by 6 (20%) major vascular complications related to TAVR but not BASILICA. There was 1 death at 30 days. There was 1 (3%) disabling stroke and 2 (7%) nondisabling strokes. Transient hemodynamic compromise was rare (7%) and resolved promptly with TAVR. CONCLUSIONS: BASILICA was feasible in both native and bioprosthetic valves. Hemodynamic compromise was uncommon. Safety was acceptable and needs confirmation in larger studies. BASILICA appears effective in preventing coronary artery obstruction from TAVR in subjects at high risk. Published by Elsevier Inc.
OBJECTIVES: The BASILICA (Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction during TAVR) investigational device exemption trial was a prospective, multicenter, single-arm safety and feasibility study. BACKGROUND:Coronary artery obstruction is a rare but devastating complication of transcatheter aortic valve replacement (TAVR). Current stent-based preventative strategies are suboptimal. Bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction during TAVR (BASILICA) is a novel transcatheter technique performed immediately before TAVR to prevent coronary artery obstruction. METHODS: Subjects with severe native or bioprosthetic aortic valve disease at high or extreme risk for surgery, and at high risk of coronary artery obstruction, were included. The primary success endpoint was successful BASILICA and TAVR without coronary obstruction or reintervention. The primary safety endpoint was freedom from major adverse cardiovascular events. Data were independently monitored. Endpoints were independently adjudicated. A core laboratory analyzed computed tomography images. RESULTS: Between February 2018 and July 2018, 30 subjects were enrolled. Primary success was met in 28 (93%) subjects. BASILICA traversal and laceration was successful in 35 of 37 (95%) attempted leaflets. There was 100% freedom from coronary obstruction and reintervention. Primary safety was met in 21 (70%), driven by 6 (20%) major vascular complications related to TAVR but not BASILICA. There was 1 death at 30 days. There was 1 (3%) disabling stroke and 2 (7%) nondisabling strokes. Transient hemodynamic compromise was rare (7%) and resolved promptly with TAVR. CONCLUSIONS: BASILICA was feasible in both native and bioprosthetic valves. Hemodynamic compromise was uncommon. Safety was acceptable and needs confirmation in larger studies. BASILICA appears effective in preventing coronary artery obstruction from TAVR in subjects at high risk. Published by Elsevier Inc.
Authors: Philipp Blanke; Jeanette Soon; Danny Dvir; Jong K Park; Christopher Naoum; Shaw-Hua Kueh; David A Wood; Bjarne L Norgaard; Kapilan Selvakumar; Jian Ye; Anson Cheung; John G Webb; Jonathon Leipsic Journal: J Cardiovasc Comput Tomogr Date: 2016-09-24
Authors: Omar K Khalique; Rebecca T Hahn; Hemal Gada; Tamim M Nazif; Torsten P Vahl; Isaac George; Bindu Kalesan; Molly Forster; Mathew B Williams; Martin B Leon; Andrew J Einstein; Todd C Pulerwitz; Gregory D N Pearson; Susheel K Kodali Journal: JACC Cardiovasc Interv Date: 2014-08 Impact factor: 11.195
Authors: Raj R Makkar; Gregory Fontana; Hasan Jilaihawi; Tarun Chakravarty; Klaus F Kofoed; Ole De Backer; Federico M Asch; Carlos E Ruiz; Niels T Olsen; Alfredo Trento; John Friedman; Daniel Berman; Wen Cheng; Mohammad Kashif; Vladimir Jelnin; Chad A Kliger; Hongfei Guo; Augusto D Pichard; Neil J Weissman; Samir Kapadia; Eric Manasse; Deepak L Bhatt; Martin B Leon; Lars Søndergaard Journal: N Engl J Med Date: 2015-10-05 Impact factor: 91.245
Authors: Henrique B Ribeiro; John G Webb; Raj R Makkar; Mauricio G Cohen; Samir R Kapadia; Susheel Kodali; Corrado Tamburino; Marco Barbanti; Tarun Chakravarty; Hasan Jilaihawi; Jean-Michel Paradis; Fabio S de Brito; Sergio J Cánovas; Asim N Cheema; Peter P de Jaegere; Raquel del Valle; Paul T L Chiam; Raúl Moreno; Gonzalo Pradas; Marc Ruel; Jorge Salgado-Fernández; Rogerio Sarmento-Leite; Hadi D Toeg; James L Velianou; Alan Zajarias; Vasilis Babaliaros; Fernando Cura; Antonio E Dager; Ganesh Manoharan; Stamatios Lerakis; Augusto D Pichard; Sam Radhakrishnan; Marco Antonio Perin; Eric Dumont; Eric Larose; Sergio G Pasian; Luis Nombela-Franco; Marina Urena; E Murat Tuzcu; Martin B Leon; Ignacio J Amat-Santos; Jonathon Leipsic; Josep Rodés-Cabau Journal: J Am Coll Cardiol Date: 2013-08-14 Impact factor: 24.094
Authors: Samir R Kapadia; Susheel Kodali; Raj Makkar; Roxana Mehran; Ronald M Lazar; Robert Zivadinov; Michael G Dwyer; Hasan Jilaihawi; Renu Virmani; Saif Anwaruddin; Vinod H Thourani; Tamim Nazif; Norman Mangner; Felix Woitek; Amar Krishnaswamy; Stephanie Mick; Tarun Chakravarty; Mamoo Nakamura; James M McCabe; Lowell Satler; Alan Zajarias; Wilson Y Szeto; Lars Svensson; Maria C Alu; Roseann M White; Carlye Kraemer; Azin Parhizgar; Martin B Leon; Axel Linke Journal: J Am Coll Cardiol Date: 2016-11-01 Impact factor: 24.094
Authors: Jaffar M Khan; Toby Rogers; William H Schenke; Jonathan R Mazal; Anthony Z Faranesh; Adam B Greenbaum; Vasilis C Babaliaros; Marcus Y Chen; Robert J Lederman Journal: JACC Cardiovasc Interv Date: 2016-09-12 Impact factor: 11.195
Authors: Danny Dvir; John G Webb; Sabine Bleiziffer; Miralem Pasic; Ron Waksman; Susheel Kodali; Marco Barbanti; Azeem Latib; Ulrich Schaefer; Josep Rodés-Cabau; Hendrik Treede; Nicolo Piazza; David Hildick-Smith; Dominique Himbert; Thomas Walther; Christian Hengstenberg; Henrik Nissen; Raffi Bekeredjian; Patrizia Presbitero; Enrico Ferrari; Amit Segev; Arend de Weger; Stephan Windecker; Neil E Moat; Massimo Napodano; Manuel Wilbring; Alfredo G Cerillo; Stephen Brecker; Didier Tchetche; Thierry Lefèvre; Federico De Marco; Claudia Fiorina; Anna Sonia Petronio; Rui C Teles; Luca Testa; Jean-Claude Laborde; Martin B Leon; Ran Kornowski Journal: JAMA Date: 2014-07 Impact factor: 56.272
Authors: Martin B Leon; Craig R Smith; Michael J Mack; Raj R Makkar; Lars G Svensson; Susheel K Kodali; Vinod H Thourani; E Murat Tuzcu; D Craig Miller; Howard C Herrmann; Darshan Doshi; David J Cohen; Augusto D Pichard; Samir Kapadia; Todd Dewey; Vasilis Babaliaros; Wilson Y Szeto; Mathew R Williams; Dean Kereiakes; Alan Zajarias; Kevin L Greason; Brian K Whisenant; Robert W Hodson; Jeffrey W Moses; Alfredo Trento; David L Brown; William F Fearon; Philippe Pibarot; Rebecca T Hahn; Wael A Jaber; William N Anderson; Maria C Alu; John G Webb Journal: N Engl J Med Date: 2016-04-02 Impact factor: 91.245
Authors: Robert J Lederman; Vasilis C Babaliaros; Toby Rogers; Jaffar M Khan; Norihiko Kamioka; Danny Dvir; Adam B Greenbaum Journal: JACC Cardiovasc Interv Date: 2019-07-08 Impact factor: 11.195
Authors: Sameer A Hirji; Edward D Percy; Cheryl K Zogg; Alexandra Malarczyk; Morgan T Harloff; Farhang Yazdchi; Tsuyoshi Kaneko Journal: Eur Heart J Date: 2020-08-01 Impact factor: 29.983
Authors: John C Lisko; Vasilis C Babaliaros; Robert J Lederman; Jaffar M Khan; Toby Rogers; Adam B Greenbaum Journal: Cardiovasc Revasc Med Date: 2019-06-06
Authors: Jaffar M Khan; Christopher G Bruce; Vasilis C Babaliaros; Adam B Greenbaum; Toby Rogers; Robert J Lederman Journal: JACC Cardiovasc Interv Date: 2020-03-23 Impact factor: 11.195
Authors: John C Lisko; Adam B Greenbaum; Robert A Guyton; Norihiko Kamioka; Kendra J Grubb; Patrick T Gleason; Isida Byku; Jose F Condado; Andres Jadue; Gaetano Paone; Peter C Block; Lucia Alvarez; Joe Xie; Jaffar M Khan; Toby Rogers; Robert J Lederman; Vasilis C Babaliaros Journal: JACC Cardiovasc Interv Date: 2020-09-30 Impact factor: 11.195
Authors: Jaffar M Khan; Toby Rogers; Adam B Greenbaum; Vasilis C Babaliaros; Dursun Korel Yildirim; Christopher G Bruce; Daniel A Herzka; William H Schenke; Kanishka Ratnayaka; Robert J Lederman Journal: J Am Coll Cardiol Date: 2020-03-31 Impact factor: 24.094
Authors: Victor X Mosquera; Alberto Bouzas-Mosquera; Yago Vilela-González; Carlos Velasco; Jorge Salgado-Fernández; Ramón Calviño-Santos; Nicolás Vázquez-González; José M Vázquez-Rodríguez; José M Herrera-Noreña Journal: Interact Cardiovasc Thorac Surg Date: 2021-07-26
Authors: Jaffar M Khan; Vasilis C Babaliaros; Adam B Greenbaum; Christian Spies; David Daniels; Jeremiah P Depta; J Bradley Oldemeyer; Brian Whisenant; James M McCabe; Kamran I Muhammad; Isaac George; Paul Mahoney; Jonas Lanz; Roger J Laham; Pinak B Shah; Adnan Chhatriwalla; Shahram Yazdani; George Hanzel; Ashish Pershad; Robert A Leonardi; Ramzi Khalil; Gilbert H L Tang; Howard C Herrmann; Shikhar Agarwal; Peter S Fail; Ming Zhang; Andrei Pop; John Lisko; Emily Perdoncin; Rachel L Koch; Itsik Ben-Dor; Lowell F Satler; Cheng Zhang; Jeffrey E Cohen; Robert J Lederman; Ron Waksman; Toby Rogers Journal: JACC Cardiovasc Interv Date: 2021-03-06 Impact factor: 11.195
Authors: Jaffar M Khan; Adam B Greenbaum; Vasilis C Babaliaros; Danny Dvir; Mark Reisman; James M McCabe; Lowell Satler; Ron Waksman; Marvin H Eng; Gaetano Paone; Marcus Y Chen; Christopher G Bruce; Annette M Stine; Xin Tian; Toby Rogers; Robert J Lederman Journal: Circ Cardiovasc Interv Date: 2021-05-18 Impact factor: 6.546